Arcutis Biotherapeutics

Chronic Skin Trends Will Boost Non-Steroidal Treatment Adoption

AnalystConsensusTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

26 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$21.86

22.7% undervalued

15 Aug

US$16.89

98.9%

14.4%

Author's Valuation

US$21.9

22.7% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Increased 2.68%

AnalystConsensusTarget Fair Value

US$21.9

22.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

25.52%

Biotech revenue growth rate

13.35%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$236.99m

Earnings '28

14.48x

PE Ratio '28

US$3.43b

Market Cap '28

US$3.43b

Market Cap '28

129.42m

No. shares '28

US$26.52

Share Price '28

US$26.52 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$21.79

Fair Value '25

Chronic Skin Trends Will Boost Non-Steroidal Treatment Adoption

Shared on01 May 25Fair value Increased 2.68%

Shared on01 May 25
Fair value Increased 2.68%